Genomic Vision Reduces Replication Combing Assay Turnaround Time for Pharmaceutical Industry and Advances Drug Discovery and Oncology

Regulatory News:

Genomic Vision (FR0011799907 – GV – the “Company”), a Euronext-listed biotechnology company that develops products and services for the highly accurate characterization of transformed cells is thrilled to present the optimized processing time of its RCA service. This innovation marks an important step for the pharmaceutical industry, aligning perfectly with its pressing demands for enhanced efficiency and rapid execution.

Initially designed for academic researchers, the RCA has undergone multiple improvements, positioning it as a leading solution for drug discovery and cancer therapy. Genomic Vision's RCA is known for its speed and effectiveness, improving cell cycle analysis.

One of Genomic Vision RCA's standout features is its time-saving capability, reducing turnaround time for 20 samples from 12 weeks to only 2 weeks. Improving both the sample processing in the lab and the analysis allowed for a 6-fold time reduction. This advancement enables pharmaceutical stakeholders to make quick, informed decisions, expediting the development of life-saving treatments to meet the fast-paced pharmaceutical requirements.

Genomic Vision's software FiberSmart, driven by AI, executes a crucial role in this performance boost. FiberSmart automates high-resolution imaging on a single-molecule scale, eliminating the need for time-consuming image reconstructions. The user-friendly interface streamlines researchers' interaction with the technology.

In the near future, Genomic Vision plans to introduce further enhancements in its software, as well as the sample processing.

In a field characterized by short timelines, RCA is a game-changing solution, facilitating decision-making, enhanced precision, and operational efficiency. Genomic Vision is commitment to advancing scientific boundaries in the area of genomic analysis for the pharmaceutical industry.

Aurélien Petit, Services and Support Director at Genomic Vision, expressed his enthusiasm, stating: "We worked hard to reduce our service time to 2 weeks so that our customers can access reliable and accurate results in record time. We are thrilled to be able to make a significant contribution to accelerating the work of pharmaceutical companies in drug discovery and oncology."

***

ABOUT GENOMIC VISION

GENOMIC VISION is a biotechnology company that develops products and services for the highly accurate characterization of genome modifications. We deliver high-quality integrated genomic analysis solutions to improve quality control and bioproduction standards of advanced gene therapies at scale. Based on molecular combing technology and artificial intelligence, The Company provides robust quantitative measurements needed for high confidence characterization of transformed cell lines and prediction of cell line performance, in particular in the context of the biomanufacturing processes of cell and gene therapies. Genomic Vision’s molecular combing technology has further applications in drug development of agents targeting DNA replication and damage response mechanisms, visualizing DNA replication kinetics and telomere length maintenance. Genomic Vision, based near Paris in Bagneux, is a public company listed in compartment C of Euronext’s regulated market in Paris (Euronext: GV – ISIN: FR0011799907).